Abstract
Peroxidation of plasma lipoproteins has been implicated in the endothelial cell activation and monocyte adhesion that initiate atherosclerosis, but the exact mechanisms underlying this activation remain unclear. Lipid peroxidation generates lipid aldehydes, including the γ-ketoaldehydes (γKA), also termed isoketals or isolevuglandins, that readily modify the amine headgroup of phosphatidylethanolamine (PE). We hypothesized that aldehyde modification of PE could mediate some of the proinflammatory effects of lipid peroxidation. We found that PE modified by γKA (γKA-PE) induced THP-1 monocyte adhesion to human umbilical cord endothelial cells. γKA-PE also induced expression of adhesion molecules and increased MCP-1 and IL-8 mRNA in human umbilical cord endothelial cells. To determine the structural requirements for γKA-PE activity, we tested several related compounds. PE modified by 4-oxo-pentanal induced THP-1 adhesion, but N-glutaroyl-PE and C18:0N-acyl-PE did not, suggesting that an N-pyrrole moiety was essential for cellular activity. As the N-pyrrole headgroup might distort the membrane, we tested the effect of the pyrrole-PEs on membrane parameters. γKA-PE and 4-oxo-pentanal significantly reduced the temperature for the liquid crystalline to hexagonal phase transition in artificial bilayers, suggesting that these pyrrole-PE markedly altered membrane curvature. Additionally, fluorescently labeled γKA-PE rapidly internalized to the endoplasmic reticulum (ER); γKA-PE induced C/EBP homologous protein CHOP and BiP expression and p38 MAPK activity, and inhibitors of ER stress reduced γKA-PE-induced C/EBP homologous protein CHOP and BiP expression as well as EC activation, consistent with γKA-PE inducing ER stress responses that have been previously linked to inflammatory chemokine expression. Thus, γKA-PE is a potential mediator of the inflammation induced by lipid peroxidation.
Keywords: Endoplasmic Reticulum(ER), Endothelium, Inflammation, Oxidative Stress, Phospholipid, Aldehydes, Isoketals, Levuglandins, Lipid Peroxidation
Introduction
Lipid peroxidation has been implicated in a host of pathological processes, including inflammation and atherosclerosis, but there is still much that is unknown about the mechanisms linking lipid peroxidation to the activation of inflammatory responses. Lipid peroxidation produces a plethora of lipid aldehydes (Fig. 1), including malondialdehyde, acrolein, and 4-hydroxynonenal (HNE).3 It also produces a large family of γ-ketoaldehydes (γKA), regioisomers that have been given the trivial name of isoketals or isolevuglandins. Exposure of vascular cells to various aldehydes results in endothelial dysfunction, secretion of cytokines, and recruitment of monocytes (1–7), all of which are key steps in the initiation of the chronic inflammatory conditions leading to atherosclerosis.
Despite these potentially important inflammatory effects, the mechanisms whereby lipid aldehydes induce their effects on vascular cells are still poorly understood. Significant effort has focused on the effects of protein and DNA modification by lipid aldehydes. However, recent studies have shown that lipid aldehydes, including malondialdehyde, acrolein, HNE, and γKA, also modify phosphatidylethanolamine (PE) in vitro (8–18) as does an aldehyde oxidation product of cholesterol (19). Of particular interest in this regard is our recent finding that treatment of human umbilical vein endothelial cells (HUVEC) with 15-E2-isoketal, one of the major γKA regioisomers, generated more modified PE (γKA-PE) than modified protein (17). Aldehyde-modified PEs, including γKA-PE, are formed in significant amounts in biological systems during oxidative stress. For instance, N-pyrrole-modified PEs (which could arise from reaction of a number of different lipid aldehydes with PE, including γKA) were detected by Ehrlich assay in HDL oxidized in vitro (20). Treatment with arachidonic acid, which induces oxidative stress and lipid peroxidation, significantly elevates levels of γKA-PE in cultured endothelial cells (21). Chronic ethanol exposure, a well characterized inducer of lipid peroxidation in vivo, significantly increases plasma levels of γKA-PEs (18). Plasma levels of γKA-PE are also increased in macular degeneration (18). Although these studies indicate that the lipid aldehydes do indeed modify PE in vivo, they do not provide any insight as to whether modification of PE contributes to the proinflammatory activities of lipid aldehydes.
We therefore examined whether γKA-PE could induce proinflammatory effects using a cell culture model of inflammation, THP-1 monocyte adhesion to HUVEC. We then examined the structural requirements for HUVEC activation by γKA-PE and related aldehyde-modified PEs and their effects on membrane bilayer properties. We also assessed the localization of γKA-PE and examined potential mechanisms of cell signaling. These studies suggest that γKA-PE and related pyrrole-PEs are an important new class of proinflammatory mediators that induce their effects through localization to the ER, alteration of membrane curvature, and activation of ER stress signaling pathways.
EXPERIMENTAL PROCEDURES
Reagents
1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (DiPoPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (LPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl) (C16:0 glutaryl-PE (glt-PE)), and 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl}-sn-glycero-3-phosphoethanolamine (NBD-PE) were purchased from Avanti Polar Lipids (Alabaster, AL). Ethanolamine (Etn), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt, and LPS were purchased from Sigma. Organic solvents, including methanol, chloroform, dichloromethane, and acetonitrile, were high performance liquid chromatography grade.
Preparation of Lipid Aldehydes and N-Modified PEs
15-E2-Isoketal, a representative regioisomer of γKA, was prepared as described previously by organic synthesis (22). The synthesis of γKA-PE and γKA-Etn by reaction of 15-E2-isoketal with DPPE or Etn, respectively, was performed following our previously described procedures (17, 21). γKA-LPE was prepared in a similar manner as γKA-PE except that LPE was used in place of DPPE. To study γKA-PE on membrane parameters, a large scale reaction mixture (100 ml) was concentrated under N2 and further purified by HPLC. The mobile phase consisted of solvent A (60:20:20 methanol, acetonitrile, 1 mm ammonium acetate) and solvent B (1 mm ammonium acetate in EtOH). The lipids were chromatographed on a Prevail C18 5u (250 × 4.6-mm) column (Alltech, Deerfield, IL) with a constant flow rate of 1 ml/min. After a 2-min hold at 20% solvent B, the solvent was gradient ramped to 100% B over 10 min, held at 100% B for 8 min, and returned to 20% B over 5 min and then held for 5 min before the next injection. The fractions containing γKA-PE were identified by negative ion LC/MS analysis (m/z 1006.7) and combined. The concentration of final product was determined by parent scan of m/z 255 in negative ion LC/MS with C17:0N-acyl-PE (m/z 942.7) as the internal standard. C17:0N-acyl-PE, as well as C18:0N-acyl-PE (NAPE, m/z 956.7), were prepared as described previously (21).
γKA-NBD-PE was prepared following the same procedure as γKA-PE except NBD-PE was used instead of PE. Excess NBD-PE was removed after reaction using the same HPLC purification method above except that the final product γKA-NBD-PE was quantified by fluorescence using the starting material as reference. 4-Oxo-pentanal (OPA) was prepared as described previously by organic synthesis (23). OPA-PE was prepared from OPA and DPPE following the same procedure as γKA-PE. The HPLC fractions containing OPA-PE were identified by negative ion LC/MS analysis (m/z 754) and combined.
Cell Culture
HUVEC obtained from the American Type Culture Collection (Manassas, VA) were cultured in endothelial basal growth medium-2 (Lonza, Basel, Switzerland) supplemented with 2% FBS, 0.4% human FGF-B, 0.1% VEGF, 0.1% recombinant long R insulin-like growth factor-B, 0.1% human epidermal growth factor, 0.1% gentamicin sulfate, 0.04% hydrocortisone, 0.1% ascorbic acid, and 0.1% heparin. Cells from passage 6 were used in this study. THP-1 cells were propagated in RPMI 1640 medium containing 10% FBS, 25 mm HEPES, 100 units/ml penicillin, 100 μg/ml streptomycin, l-glutamine, and 50 μmol/liter β-mercaptoethanol.
Preparation of HUVEC Stimulation Solutions
Stimulation solutions of γKA-PE and its analogs were prepared from stock solutions of each N-modified PE by evaporating off the organic solvent to dryness, redissolving the N-modified PEs in ethanol, diluting to the appropriate concentration using HBSS or DMEM containing 0.1% human serum albumin (HSA), and then sonicating the solution in a water bath sonicator. The final concentration of ethanol was 0.5% or less in all stimulation solutions. Because γKA reacts with the primary amines and is soluble in 0.5% ethanol without the use of HSA, for adhesion assays comparing the potency of γKA with γKA-PE and its analogs, we omitted 0.1% HSA from experiments where γKA itself was tested and used HBSS, rather than DMEM, because DMEM contains amino acids.
Cell Adhesion Assay
HUVEC (passage 6) were seeded on 0.1% gelatin-coated 96-well culture plates and cultured to 80–90% confluence. Cells were washed with HBSS three times and incubated with vehicle (negative control), LPS (positive control), or the test compound in HBSS at 37 °C for 4 h. The media were removed, and HUVEC cells were washed with HBSS three times prior to adding 100 μl of calcein-labeled THP-1 cells for 1 h at 37 °C. Calcein-labeled THP-1 cells were prepared by incubation with 4 μg/ml calcein acetoxymethyl ester (Invitrogen) at 37 °C for 30 min; excess label was removed by washing three times, and the THP-1 were resuspended in HBSS at 5 × 106 cell/ml. Nonadherent THP-1 cells were removed from HUVEC by gently washing with PBS twice, and the fluorescence of HUVEC-bound THP-1 cells was measured (494 excitation/520 emission). The extent of treatment-induced adhesion for each well was normalized to increase over basal fluorescence in vehicle-treated wells induced by 10 μg/ml LPS. For each compound, a minimum of three separate experiments with five replicate wells per experiment were performed.
To determine the solubility of γKA-PE and its analogs in stimulation solutions used for cultured cell experiments, we prepared solutions containing 1 μm each of γKA-PE, C18:0-N-acyl-PE, OPA-PE, and glt-PE in either methanol/chloroform (9:1) or in DMEM containing 0.1% HSA and 0.5% ethanol. The N-modified PE in the media were then extracted using 2 volumes of chloroform/methanol (2:1); C17:0NAPE was added as internal standard, and the amount of N-modified PE was quantified by mass spectrometry. Solubility was calculated as the amount of N-modified PE measured in the extract of the DMEM, 0.1% HSA compared with that measured in the methanol/chloroform sample. The solubility of each PE in DMEM, 0.1% HSA was as follows: glt-PE, 118%; C18:0NAPE, 107%; OPA-PE, 85%; and γKA-PE, 109%. Therefore, all of the N-modified PEs appeared to be highly soluble in stimulation media. To assess the extent that each N-modified PE as incorporated by HUVEC, we incubated the mixture containing 1 μm of each N-modified PE dissolved in the DMEM, 0.1% HSA, 0.5% ethanol with triplicate wells of HUVEC for 4 h, removed the mixture, washed the cells twice, added C17:0NAPE as internal standard, extracted the cellular phospholipids with chloroform/methanol (2:1) solution, and then analyzed by mass spectrometry. Incorporation of each of the N-modified PEs was as follows: glt-PE, 28%; C18:0NAPE, 33%; OPA-PE, 7%; and γKA-PE, 10%.
Expression of Adhesion Molecules
HUVEC (passage 6) were seeded and treated as described above, except that HUVEC were incubated with serum-free DMEM for 1 h prior to treatment with vehicle, γKA-PE, or LPS in DMEM with 0.1% HSA for 4 h. Cell-based ELISAs were then performed as described previously (24). Briefly, cells were washed with PBS containing 0.1% Tween (pH 7.4) and fixed with 1% paraformaldehyde for 0.5 h at room temperature. Excess paraformaldehyde was quenched by incubation with 1% glycine for 1 h. Primary antibodies against ICAM-1 (sc-18853, Santa Cruz Biotechnology, Santa Cruz, CA), VCAM-1 (sc-8304, Santa Cruz Biotechnology), or E-selectin (sc-14011, Santa Cruz Biotechnology) was added to each well and incubated at 4 °C overnight. The wells were washed; HRP-conjugated anti-mouse IgG antibody (Promega, Madison, WI) was added for 1 h, and the immunocomplexes were quantified by absorbance at 405 nm using 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt as peroxidase substrate. Expression was expressed as fold vehicle-only control.
Chemokine mRNA Expression
Levels of IL-8, MCP-1, and GAPDH mRNAs were measured after conversion to cDNA by quantitative real time PCR using IQ SYBR Green supermix (Bio-Rad). The primer pairs for each gene are listed as follows: (a) human IL-8 (NM_000584, from Sigma): sense GAG TGC TAA AGA ACT TAG ATG TCA G, antisense GCT TTA CAA TAA TTT CTG TGT TGG C, and probe TGG TCC ACT CTC AAT CAC TCT CAG T; (b) human MCP-1 (NM-002982, CCL2, from Sigma): sense CTC TCG CCT CCA GCA TGA AAG, antisense AGG TGA CTG GGG CAT TGA TTG, and probe CTG CCG CCC TTC TGT GCC TGC TG; and (c) human GAPDH (NM_002046 GAPDH, from Sigma): sense CAA AAT CAA GTG GGG CGA TGC, antisense CAA ATG AGC CCC AGC CTT CTC, and probe AGT CCA CTG GCG TCT TCA CCA CCT T. Data from five separated experiments were averaged.
Membrane Curvature and TH
Shifts in the bilayer to hexagonal phase transition temperature of DiPoPE (TH) upon addition of a membrane additive is a sensitive indicator of the effect of the additive on membrane curvature (25). Lipid films were made by first dissolving DiPoPE with or without a modified PE in chloroform/methanol, 2:1 (v/v), at the appropriate ratios. The solvents were driven off by a stream of nitrogen, and the samples were kept for 3 h under high vacuum to remove the last traces of solvent. Dry lipid films were suspended in 20 mm PIPES, 1 mm EDTA, 150 mm NaCl (pH 7.4) by vortexing to form multilamellar vesicles. The concentration of lipid in the samples studied was maintained at 2.5 mg/ml. Differential scanning calorimetry measurements were made using a Nano II differential scanning calorimeter (Calorimetry Sciences Corp., Lindon, UT). The cell volume was 340 μl. The scan rate was 1 °C/min with a delay of 5 min between sequential scans in a series to allow for thermal equilibration. The features of the design of this instrument have been described (26). The calorimetry curves were analyzed by using the fitting program, DA-2, provided by Microcal Inc. (Northampton, MA), and plotted with Origin, version 7.0.
Localization of γKA-PE
HUVECs were treated with 1 μm γKA-NBD-PE for 1 h at 4 °C to allow the modified PE to accumulate in the plasma membrane of the cell. After 1 h, the cells were transferred to a humid incubator at 37 °C for 15 min, then washed twice with PBS, and fixed for 15 min with 2.5% paraformaldehyde in PBS at room temperature. After fixation, the cells were rinsed three times with PBS containing 1% BSA and 0.1% saponin for 5 min per wash. The cells were then incubated in a humid chamber in the presence of the mouse anti-calnexin antibody (Cell Signaling Technology, Danvers, MA) overnight at 4 °C. After incubating, the cells were rinsed four times in blocking buffer and then incubated with a goat anti-mouse antibody labeled with Alexa 547 fluorophore (Invitrogen) for 1 h at room temperature. At that point, the antibodies were fixed in place using 2.5% paraformaldehyde for 15 min at room temperature. Imaging was performed using a Zeiss Axioplan imaging upright microscope (Zeiss, Germany) using MetaMorph as the imaging software (Molecular Devices Inc.)
To determine whether γKA-NBD-PE remained intact or was hydrolyzed during the incubation with HUVEC prior to fluorescence imaging, we incubated γKA-NBD-PE with either cell-free buffer or with HUVEC for 1 h at 4 °C and then for 15 min at 37 °C. After this incubation period, the solution was removed from cells; lipids were extracted using acidic modified Bligh-Dyer to ensure extraction of NBD-fatty acid metabolites, and the products were analyzed by TLC using chloroform, methanol, ethanol, ethyl acetate, 0.25% potassium chloride (10:4:10:10:3.6) as solvent. γKA-NBD-PE and γKA-NBD-PE treated with Streptomyces chromofuscus phospholipase D (to produce NBD-phosphatidic acid), and γKA-NBD-PE treated with 0.35 n sodium hydroxide (to produce NBD-fatty acid) were used as references. By this analysis, the majority of NBD label remained as intact γKA-NBD-PE. The identity of the major NBD component as γKA-NBD-PE was verified by mass spectrometry.
Immunoblotting of ER Stress Response Proteins
HUVEC were cultured in 100-mm dishes and treated with 3 μm PE or 3 μm γKA-PE for the designated time. After treatment, cells were washed, scraped, centrifuged, and resuspended in lysis buffer (prepared from 20× lysis buffer stock (C7027, Invitrogen) with complete protease inhibitor mixture (Roche Applied Science), 1 mm sodium orthovanadate, 1 mm sodium fluoride, 1 mm sodium molybdate, and 10 mm β-glycerophosphate added), and incubated on ice for 30 min. Lysates were then centrifuged to remove debris and stored at −20 °C until immunoblot analysis. 20 μl of lysate for each sample were separated by SDS-PAGE and transferred to PVDF membrane, and the membrane was cut into three strips for immunoblotting of appropriate ER stress response proteins as follows: <30 kDa (for CHOP), 34–70 kDa (for phospho-p38), and >70 kDa (for BiP/grp78). Each strip was incubated with appropriate primary antibody for CHOP (L63F7, Cell Signaling Technology), BiP/grp78 (C50B12, Cell Signaling Technology), or phospho-p38 (9211S, Cell Signaling Technology) and then visualized using fluorescent anti-mouse or anti-rabbit IgG antibody and scanned by the Odyssey Imaging System (LI-COR Biosciences). After phospho-p38 immunoblotting, the membrane was stripped using Western blot stripping buffer (Pierce, 21059) and re-immunoblotted using antibody for actin (sc-1616-R, Santa Cruz Biotechnology). Data from five separated experiments was analyzed by blot volume (INT/mm2) with Quantity One software (Bio-Rad). Actin volume was used for normalization. In two replicate experiments, total p38 (9212, Cell Signaling Technology) at the 60-min time point was also measured by immunoblotting, and the ratio of phospho-p38 to total p38 was determined.
Inhibition of ER Stress Response
Two commonly used ER stress response inhibitors, tauroursodeoxycholic acid (TUDCA) and 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), were used to test the effect of inhibiting ER stress response signaling. Confluent HUVEC were pretreated with either vehicle, 300 μm AEBSF, or 300 μm TUDCA for 1 h, and the pretreatment media were removed and replaced with stimulation buffer containing γKA-PE. For experiments to measure CHOP and BiP expression, 100-mm dishes were used, and lysate preparation and immunoblotting were performed as described above with HUVEC being stimulated with 3 μm γKA-PE for 1 h. For adhesion assays, 96-well plates were used, and HUVEC were stimulated with 2 or 5 μm γKA-PE for 4 h prior to performing the THP-1 adhesion assay as described above.
Statistical Analysis
All statistical analysis was performed using Graph Pad Prism 4.03 (GraphPad Software, La Jolla, CA).
RESULTS
PE Modified by an Endogenous γ-Ketoaldehyde Induces Endothelial Cell Activation
ROS have previously been associated with activation of endothelial cells and inflammation. We hypothesized that formation of γKA-PE (or its metabolites) would be an important mediator of ROS-induced inflammation (Fig. 2A). To confirm that ROS induced inflammation, we treated confluent monolayers of HUVEC with 0–1 mm H2O2 and then measured the adhesion of calcein-labeled THP-1 monocytes to the stimulated HUVEC by fluorescence. THP-1 adhesion was normalized as the percent of fluorescence induced by 10 μg/ml LPS after subtraction of base-line fluorescence in vehicle-only treated cells. H2O2 dose-dependently (EC50 0.13 mm) induced adhesion of THP-1 monocytes to HUVEC (Fig. 2B). We then tested if 15-E2-isoketal, one of the eight regioisomers of γKA that are generated by peroxidation of arachidonic acid and that are the immediate precursors to γKA-PE, could also induce similar effects. We found that γKA also dose-dependently (EC50 3.5 μm) increased THP-1 adhesion to HUVEC (Fig. 2C). We have previously shown that the major product formed when γKA is added to HUVEC is γKA-PE, although γKA protein adducts form as well (17). To determine whether the formation of γKA-PE was sufficient to induce HUVEC activation, we synthesized γKA-PE using 15-E2-isoketal as a representative regioisomer, and we tested its effect on HUVEC. Direct addition of γKA-PE to HUVEC dose-dependently (EC50 2.5 μm) increased THP-1 binding to HUVEC (Fig. 2D).
Some N-modified PEs (e.g. NAPE) require hydrolysis of the parent phospholipid to generate the bioactive compound (i.e. N-acylethanolamides). Although the metabolism of γKA-PE in HUVEC has not been studied, purified PLA2 can hydrolyze γKA-PE in vitro to its lyso-PE analog (γKA-LPE) (18), and we have shown that phospholipase D isolated from S. chromofuscus can hydrolyze γKA-PE in vitro to its ethanolamine analog (γKA-Etn) (17). To test whether these potential metabolites of γKA-PE might be the actual active form of γKA-PE, we synthesized γKA-LPE and γKA-Etn and tested their effects on HUVEC. Although both γKA-LPE and γKA-Etn dose-dependently induced THP-1 adhesion to HUVEC, neither γKA-LPE (EC50 11.1 μm, Fig. 2E) nor γKA-Etn (EC50 18.6 μm, Fig. 2F) were as potent as γKA-PE itself, suggesting that hydrolysis of γKA-PE was not necessary for its activity.
γKA-PE Induces Expression of Adhesion Molecules and Chemokine Secretion
Attraction and tight adhesion of leukocytes to endothelial cells usually require expression of chemokines such as MCP-1 and IL-8 as well as surface display of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin. We therefore investigated whether γKA-PE induced expression of these molecules in HUVEC. After treatment of HUVEC with γKA-PE for 4 h, we observed a dose-dependent increase in the expression levels of ICAM-1 (one-way ANOVA, p < 0.0001; Fig. 3A), VCAM-1 (one-way ANOVA, p < 0.0001; Fig. 3B), and E-selectin (one-way ANOVA, p = 0.0149; Fig. 3C). After treatment of HUVEC with γKA-PE, we also detected significant increases by quantitative real time PCR in mRNA levels of both MCP-1 (Fig. 4A) and IL-8 (Fig. 4B). These observations are consistent with γKA-PE inducing THP-1 monocyte adhesion by standard proinflammatory mechanisms.
Pyrrole Moiety Is the Key Structural Feature for γKA-PE Activity
We next sought to understand the structural components that were required for γKA-PE activity. In particular, we hypothesized that the side chain with the carboxylate anion moiety, which we anticipated would form a “lipid whisker”-like structure, would be important for activity, as lipid whiskers appear to be a key structural determinant of the activity of proinflammatory oxidized phosphatidylcholines (oxPCs). We also considered the possibility that the two other structural features of γKA-PE, a large aliphatic headgroup or the pyrrole moiety, might also be required for bioactivity. To determine whether any of these structural features were required for activity, we analyzed a series of γKA-PE analogs for their ability to activate HUVEC (Fig. 5A). To test the requirement for a carboxylate acyl chain, we used N-glutaroyl-PE. To test the requirement for a large aliphatic headgroup, we used C18:0N-acyl-PE (NAPE). To test the requirement for a pyrrole headgroup, we reacted OPA with PE and isolated the resulting pyrrole adduct (OPA-PE). We then tested 5 μm of each of these compounds in the THP-1 adhesion assay. OPA-PE induced HUVEC activation to nearly the same extent as LPS and γKA-PE, whereas NAPE and glt-PE failed to induce cell adhesion (Fig. 5B). Higher concentrations of NAPE and glt-PE (25 μm) also failed to induce cell adhesion (data not shown.) The failure to induce cell adhesion was not due to lack of incorporation into HUVEC, as glt-PE and NAPE were incorporated to a slightly greater extent than γKA-PE. These results suggested that the pyrrole moiety of γKA-PE was the key structure required for its activity.
PE Modified with Pyrrole Moieties Alters Membrane Bilayers
Membrane structure has a critical impact on cell function and membrane protein activities. One important property of both biological and model membranes is membrane curvature (27, 28), which has been shown to be important for the functioning of the endoplasmic reticulum (28–31). We hypothesized that modification of PE by pyrrole-forming aldehydes would significantly alter intrinsic membrane monolayer curvature as the pyrrole moiety seems likely to partition near the bilayer/aqueous interface, thereby disrupting normal packing and increasing the lateral pressure at some depth in the membrane (Fig. 5A). A consequence of such lateral pressure would be to increase the negative curvature of the monolayer in which these modified PEs are inserted. A simple and convenient measure of curvature tendency is to determine shifts in the bilayer to TH of a model membrane composed of DiPoPE. We therefore investigated the effect of γKA-PE and its analogs on the TH of DiPoPE using differential scanning calorimetry (Fig. 6A). For each set of differential scanning calorimetry curves generated, TH was plotted against the mole fraction of modified PE. A representative plot from a one set of differential scanning calorimetry curves for each modified PE is shown in Fig. 6B. TH varied slightly when measured over a longer period of time or with different batches of the same lipid. All measurements were repeated at least twice, and the calculated temperature shifts and deviations are summarized in Table 1.
TABLE 1.
Additive | Shift in TH |
---|---|
degrees/mol fraction | |
γKA-PE | −710 ± 90 |
OPA-PE | −600 ± 110 |
glt-PE | +480 ± 70 |
γKA-PE and OPA-PE showed similar behavior, with increasing concentrations of these compounds resulting in a significant broadening of the transition and a lowering of the transition temperature for formation of TH. This is shown in both heating and cooling curves. Such changes are consistent with these pyrrole-containing PEs increasing negative membrane curvature. In contrast, glt-PE did not broaden the transition and significantly increased the TH, consistent with it having opposite effects and promoting positive curvature.
γKA-PE Localizes to the Endoplasmic Reticulum
Various lipid mediators have been shown to exert their effects by various mechanisms, including through G-protein-coupled receptors at the plasma membrane, nuclear receptors in the nucleus, stress signaling kinases in the cytoplasm, and stress response receptors in the mitochondria and the endoplasmic reticulum. To gain insight into the cellular compartment where γKA-PE activated signaling, we synthesized a fluorescently labeled γKA-PE analog, γKA-NBD-PE. We then incubated HUVEC with γKA-NBD-PE at 4 °C for 1 h to load the plasma membrane and then initiated intracellular trafficking by raising the incubation temperature to 37 °C. After 15 min, the cells were fixed, and the localization of γKA-NBD-PE was visualized by fluorescence microscopy. When extracts of replicate-treated HUVEC were analyzed by thin layer chromatography, the major NBD-labeled compound migrated similarly to the starting γKA-NBD-PE, indicating that intracellular fluorescence represented largely intact γKA-NBD-PE (data not shown). Fluorescence imaging revealed that γKA-NBD-PE was quickly trafficked to the perinuclear region characteristic of endoplasmic reticulum (Fig. 7). Immunochemical staining of calnexin, an ER membrane marker, demonstrated significant co-localization of γKA-NBD-PE and calnexin, consistent with γKA-NBD-PE localization to ER membranes.
γKA-PE Initiates ER Stress Response Signaling
The localization of γKA-PE to the ER and the marked membrane disrupting effects of γKA-PE suggested to us the possibility that γKA-PE might invoke HUVEC activation via ER stress signaling. ER stress is sensed by the following three transmembrane proteins in the ER: PERK, IRE1, and ATF6. These three proteins result in the coordinate expression of a host of responses, including increased expression of CHOP and the ER chaperone protein BiP, as well as activation of the stress response kinase p38 MAPK via phosphorylation. To test whether γKA-PE induced ER stress response signaling, we treated HUVEC cells with either 3 μm PE (control) or γKA-PE for 10, 30, and 60 min and quantified the expression of CHOP, BiP, and phospho-p38 MAPK by immunoblotting (Fig. 8A). Treatment with γKA-PE resulted in ∼3-fold higher levels of CHOP compared with PE at all three of the tested time points (Fig. 8B), as well increased BiP expression (Fig. 8C) and phospho-p38 MAPK (Fig. 8D). Increased rate of phosphorylation, rather than increased expression of p38 MAPK appeared to underlie the increase in phospho-p38 MAPK, as γKA-PE increased the phospho-p38 MAPK to total p38 MAPK ratio about 2-fold (data not shown). Thus, γKA-PE induces at least some representative elements of the ER stress response.
Inhibitors of ER Stress Response Modulate γKA-PE-Induced EC Activation
Because ER stress response signaling has been previously implicated in the induction of inflammatory chemokines (32, 33), we tested the effects of two chemical inhibitors of the ER stress response, TUDCA and AEBSF, on γKA-PE induced responses. TUDCA is a chemical chaperone that inhibits the ER stress response induced by a variety of effectors, including tunicamycin (34), thapsigargin (35), and free fatty acids (36). AEBSF is a broad spectrum serine protease inhibitor that prevents site 1 protease cleavage of ATF6, a required step in the activation of the ATF6 arm of the ER stress response (37). Preincubation for 1 h with either AEBSF (300 μm) or TUDCA (300 μm) inhibited the expression of CHOP (Fig. 9A) or BiP (Fig. 9B) induced by 3 μm γKA-PE. We then tested the effects of inhibiting this ER stress response signaling on the ability of γKA-PE to induce THP-1 adhesion to HUVEC. AEBSF inhibited THP-1 adhesion induced in response to HUVEC stimulation with 2 and 5 μm γKA-PE by 57 and 33%, respectively (Fig. 9C). TUDCA inhibited THP-1 adhesion in response to 2 and 5 μm γKA-PE by 78 and 64%, respectively (Fig. 9D). Therefore, inhibiting the ER stress response signaling by two unrelated mechanisms both leads to significantly lower induction of inflammatory responses by γKA-PE, suggesting that γKA-PE induces its effect at least in part by inducing ER stress.
DISCUSSION
The biological effects of reactive lipid aldehydes have generally been thought to result from protein and DNA modification. Our results demonstrate that PE modification is also biologically important because PE modified by γKA activates the proinflammatory response of endothelial cells. Furthermore, modification of PE may be the primary mechanism whereby γKA induces its inflammatory effect on these cells, because γKA-PE was at least as potent as γKA itself, and we had previously found that modified PE is the major product in γKA-treated endothelial cells (17). Because oxidative stress increases plasma levels of γKA-PE (18), our results suggest the possibility that the oxidative stress associated with the early stages of atherosclerosis generates γKA-PE that then contributes to the activation of endothelial cells and atherogenesis.
Whether sufficient levels of γKA-PE or other pyrrole-PEs are generated in the vascular wall during the early stages of atherosclerosis to induce inflammatory effects remains to be determined. Although relatively high concentrations of γKA-PE (1–3 μm) were required to activate inflammatory responses in our cultured HUVEC, only ∼10% of γKA-PE incorporated into the cells during the assay. This is important to keep in mind as the mole fraction of γKA-PE in the membrane may be more relevant than the concentration in solution. When γKA-PE is generated endogenously, almost all of it would be expected to remain in the membrane due to its poor solubility in water. The concentration of γKA-PE found in whole livers of mice chronically fed ethanol was found to be ∼30 nm (18). These levels of γKA-PE may be sufficient to induce inflammation, especially if the formation of γKA-PE in these livers is localized to the membrane of vascular cells rather than homogeneously diffuse. Our findings provide a clear rationale for future studies to directly determine the levels of γKA-PE generated in vascular membranes during early atherogenesis and other inflammatory conditions.
Our results demonstrate that γKA-PE differed from the previously described class of proinflammatory phospholipids, the CD36-binding oxPCs (38, 39). Unlike oxPCs, where the lipid whisker moiety confers activity (40), the N-pyrrole moiety of γKA-PE appears to be sufficient to confer activity because OPA-PE, which lacks any lipid-whisker moiety, was also active. This result raises the possibility that other pyrrole-modified PEs will also initiate endothelial activation and inflammation. Lipid peroxidation generates several other aldehydes besides γKAs that form pyrrole adducts, which include oxoalkenals (e.g. 4-oxo-nonenal (41)), hydroxyalkenals (e.g. 4-hydroxynonenal (42)), and epoxyalkenals (e.g. 4,5-epoxydecenal (43)). Important in this regard is the previous finding that the in vitro oxidation of HDL, which converts HDL from an anti-inflammatory particle to a proinflammatory one, also generates large amounts of pyrrole-PEs (20). In addition to lipid peroxidation, oxidative degradation of glucose also forms pyrrole adducts (44), and levels of glycated PE increase during diabetes (45). Thus, several different pathways are likely to yield pyrrole PEs, and our findings suggest that such pyrrole PEs could potentially be a new class of proinflammatory phospholipids.
Although both γKA-PE and oxPCs induce inflammatory responses, the effect of γKA-PE on membrane intrinsic curvature is opposite that for oxPCs. Bioactive oxPCs have a polar sn-2 acyl chain that appears to protrude from the bilayer to form a lipid whisker (40). The absence of this oxidized acyl chain in the bilayer should reduce the lateral pressure in the nonpolar region of the membrane and thereby increase positive membrane curvature (i.e. convex shape). Consistent with this expected effect, addition of oxPCs to PE bilayers increases TH (46). In this study, we found that glt-PE, which should also form lipid whiskers, increased TH as well. In contrast, the two pyrrole-PEs markedly reduced TH and would therefore be expected to confer negative curvature (i.e. concave shape.)
Although oxPCs and pyrrole PEs have opposing effects on intrinsic membrane curvature, these opposing effects may be complementary in terms of overall physical curvature of the membrane because the major fraction of PC and PE reside on opposite monolayers of the membrane bilayer in cells. Thus, modification of PC and PE on these opposite monolayers, with their inverse effects on each monolayer, would cooperate to curve the membrane in the same direction. Such opposite, but cooperative, curvature of each monolayer has been demonstrated for the formation of membrane pores during membrane fusion promoted by viral fusion proteins (47).
Our finding that γKA-PE can invoke both ER stress signaling and inflammatory cytokines and that chemical inhibitors of the ER stress response reduce the extent to which γKA-PE activates inflammatory responses is consistent with a developing paradigm linking oxidized lipids, ER stress, inflammation, and atherosclerosis. ER stress response proteins are markedly increased in atherosclerotic lesions (48). Treatment of human endothelial cells with oxidized LDL induces all three of the transmembrane sensors for ER stress, including phosphorylation of PERK and IRE1 and ATF6 nuclear translocation (49). OxPC induces mRNA for ATF4 and the spliced (active) version of XBP1, which are important downstream mediators of ER stress signaling (50), and silencing these two genes dramatically reduces oxPC induced IL-8 and MCP-1 expression (32). Treatment of human endothelial cells with acrolein and HNE also induces ER stress as indicated by spliced XBP-1, ATF4 nuclear localization, and increased levels of CHOP mRNA (33, 51). Furthermore, inhibition of ER stress blocks acrolein-induced increases in mRNA levels of the proinflammatory cytokines TNFα, IL-6, and IL-8 (33). As γKA, HNE, and acrolein all modify PE (8, 11, 13, 15–18), our finding that γKA-PE induces CHOP, IL-8, and MCP-1 expression raises the possibility that these other aldehydes also mediate their inflammatory effects by forming modified PE, which induce ER stress responses.
One key question that remains unanswered is the exact mechanism whereby oxidatively modified phospholipids activate ER stress signaling. Our studies suggest that γKA-PE formed at the plasma membrane will rapidly translocate to the ER and potentially alter ER curvature. One caveat in interpreting our localization study is that the presence of an NBD label on γKA-NBD-PE might have caused it to partition somewhat differently than endogenously formed native γKA-PE. Thus, future studies will be needed to confirm that cells undergoing endogenous lipid peroxidation do in fact accumulate γKA-PE in their ER. Although ER stress is generally thought of in terms of the accumulation of unfolded proteins during protein synthesis, the ER is also the site of phospholipid and cholesterol synthesis. Overloading cells with free cholesterol or free fatty acid can induce ER stress responses (36, 52, 53). Therefore, it seems plausible that ER stress response signals might be triggered by the accumulation of the modified version of any ER product and not simply unfolded proteins. Future studies are needed to test whether γKA-PE does indeed alter ER membrane curvature and whether such alteration lead to conformational changes in and the activation of PERK, IRE1, and ATF6.
Acknowledgment
We thank Summer Young for valuable technical advice.
This work was supported, in whole or in part, by National Institutes of Health Grants OD003137-01 (to S. S. D.) and UL1 RR024975 (to Vanderbilt Institute for Clinical and Translation Research). This work was also supported by Vanderbilt Department of Pharmacology (to S. S. D.) and Heart and Stroke Foundation of Ontario Grant T6915 (to R. M. E.).
- HNE
- 4-hydroxynonenal
- γKA
- γ-ketoaldehyde regiosomer 15-E2-isoketal
- PE
- phosphatidylethanolamine
- NAPE
- N-acyl-PE
- γKA-PE
- PE modified by γKA
- OPA-PE
- PE modified by 4-oxo-pentanal
- DiPoPE
- dipalmitoleoylphosphatidylethanolamine
- OPA
- 4-oxo-pentanal
- DiPoPE
- 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine
- DPPE
- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
- LPE
- 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
- N-glutaryl-PE
- glt-PE, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl)
- NBD-PE
- 1-palmitoyl-2-{12-[(7-nitro-2–1,3-benzoxadiazol-4-yl)amino]lauroyl}-sn-glycero-3-phosphoethanolamine
- Etn
- ethanolamine
- oxPCs
- oxidized phosphatidylcholines
- HUVEC
- human umbilical cord endothelial cell
- TH
- hexagonal phase transition
- ER
- endoplasmic reticulum
- ROS
- reactive oxygen species
- TUDCA
- tauroursodeoxycholic acid
- AEBSF
- 4-(2-aminoethyl)benzenesulfonyl fluoride
- HBSS
- Hanks' buffered saline solution
- ANOVA
- analysis of variance
- HSA
- human serum albumin
- CHOP
- C/EBP homologous protein CHOP.
REFERENCES
- 1. Go Y. M., Halvey P. J., Hansen J. M., Reed M., Pohl J., Jones D. P. (2007) Am. J. Pathol. 171, 1670–1681 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Shanmugam N., Figarola J. L., Li Y., Swiderski P. M., Rahbar S., Natarajan R. (2008) Diabetes 57, 879–888 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Yamawaki H., Saito K., Okada M., Hara Y. (2008) Am. J. Physiol. Cell Physiol. 295, C1510–C1517 [DOI] [PubMed] [Google Scholar]
- 4. Nitti M., Domenicotti C., d'Abramo C., Assereto S., Cottalasso D., Melloni E., Poli G., Biasi F., Marinari U. M., Pronzato M. A. (2002) Biochem. Biophys. Res. Commun. 294, 547–552 [DOI] [PubMed] [Google Scholar]
- 5. Hill G. E., Miller J. A., Baxter B. T., Klassen L. W., Duryee M. J., Tuma D. J., Thiele G. M. (1998) Atherosclerosis 141, 107–116 [DOI] [PubMed] [Google Scholar]
- 6. Lee J. Y., Je J. H., Kim D. H., Chung S. W., Zou Y., Kim N. D., Ae Yoo M., Suck Baik H., Yu B. P., Chung H. Y. (2004) Eur. J. Biochem. 271, 1339–1347 [DOI] [PubMed] [Google Scholar]
- 7. Moretto N., Facchinetti F., Southworth T., Civelli M., Singh D., Patacchini R. (2009) Am. J. Physiol. Lung Cell Mol. Physiol. 296, L839–L848 [DOI] [PubMed] [Google Scholar]
- 8. Zemski Berry K. A., Murphy R. C. (2007) Chem. Res. Toxicol. 20, 1342–1351 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Balasubramanian K., Bevers E. M., Willems G. M., Schroit A. J. (2001) Biochemistry 40, 8672–8676 [DOI] [PubMed] [Google Scholar]
- 10. Bhuyan K. C., Master R. W., Coles R. S., Bhuyan D. K. (1986) Mech. Ageing Dev. 34, 289–296 [DOI] [PubMed] [Google Scholar]
- 11. Guichardant M., Taibi-Tronche P., Fay L. B., Lagarde M. (1998) Free Radic. Biol. Med. 25, 1049–1056 [DOI] [PubMed] [Google Scholar]
- 12. Guichardant M., Bernoud-Hubac N., Chantegrel B., Deshayes C., Lagarde M. (2002) Prostaglandins Leukot. Essent. Fatty Acids 67, 147–149 [DOI] [PubMed] [Google Scholar]
- 13. Bacot S., Bernoud-Hubac N., Baddas N., Chantegrel B., Deshayes C., Doutheau A., Lagarde M., Guichardant M. (2003) J. Lipid Res. 44, 917–926 [DOI] [PubMed] [Google Scholar]
- 14. Stadelmann-Ingrand S., Pontcharraud R., Fauconneau B. (2004) Chem. Phys. Lipids 131, 93–105 [DOI] [PubMed] [Google Scholar]
- 15. Bacot S., Bernoud-Hubac N., Chantegrel B., Deshayes C., Doutheau A., Ponsin G., Lagarde M., Guichardant M. (2007) J. Lipid Res. 48, 816–825 [DOI] [PubMed] [Google Scholar]
- 16. Bernoud-Hubac N., Fay L. B., Armarnath V., Guichardant M., Bacot S., Davies S. S., Roberts L. J., 2nd, Lagarde M. (2004) Free Radic. Biol. Med. 37, 1604–1611 [DOI] [PubMed] [Google Scholar]
- 17. Sullivan C. B., Matafonova E., Roberts L. J., 2nd, Amarnath V., Davies S. S. (2010) J. Lipid Res. 51, 999–1009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Li W., Laird J. M., Lu L., Roychowdhury S., Nagy L. E., Zhou R., Crabb J. W., Salomon R. G. (2009) Free Radic. Biol. Med. 47, 1539–1552 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Bach D., Epand R. F., Epand R. M., Miller I. R., Wachtel E. (2009) Chem. Phys. Lipids 161, 95–102 [DOI] [PubMed] [Google Scholar]
- 20. Hidalgo F. J., Nogales F., Zamora R. (2004) Anal. Biochem. 334, 155–163 [DOI] [PubMed] [Google Scholar]
- 21. Guo L., Amarnath V., Davies S. S. (2010) Anal. Biochem. 405, 236–245 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Amarnath V., Amarnath K., Matherson T., Davies S., Roberts L. J. (2005) Synthetic Commun. 35, 397–408 [Google Scholar]
- 23. Amarnath V., Amarnath K., Amarnath K., Davies S., Roberts L. J., 2nd. (2004) Chem. Res. Toxicol. 17, 410–415 [DOI] [PubMed] [Google Scholar]
- 24. Kilgore K. S., Shen J. P., Miller B. F., Ward P. A., Warren J. S. (1995) J. Immunol. 155, 1434–1441 [PubMed] [Google Scholar]
- 25. Epand R. M. (1985) Biochemistry 24, 7092–7095 [DOI] [PubMed] [Google Scholar]
- 26. Privalov G., Kavina V., Freire E., Privalov P. L. (1995) Anal. Biochem. 232, 79–85 [DOI] [PubMed] [Google Scholar]
- 27. Graham T. R., Kozlov M. M. (2010) Curr. Opin. Cell Biol. 22, 430–436 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Shibata Y., Hu J., Kozlov M. M., Rapoport T. A. (2009) Annu. Rev. Cell Dev. Biol. 25, 329–354 [DOI] [PubMed] [Google Scholar]
- 29. Friedman J. R., Webster B. M., Mastronarde D. N., Verhey K. J., Voeltz G. K. (2010) J. Cell Biol. 190, 363–375 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Park S. H., Blackstone C. (2010) EMBO Rep. 11, 515–521 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Settles E. I., Loftus A. F., McKeown A. N., Parthasarathy R. (2010) Biophys. J. 99, 1539–1545 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Gargalovic P. S., Gharavi N. M., Clark M. J., Pagnon J., Yang W. P., He A., Truong A., Baruch-Oren T., Berliner J. A., Kirchgessner T. G., Lusis A. J. (2006) Arterioscler. Thromb. Vasc. Biol. 26, 2490–2496 [DOI] [PubMed] [Google Scholar]
- 33. Haberzettl P., Vladykovskaya E., Srivastava S., Bhatnagar A. (2009) Toxicol. Appl. Pharmacol. 234, 14–24 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R. O., Görgün C. Z., Hotamisligil G. S. (2006) Science 313, 1137–1140 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Lee Y. Y., Hong S. H., Lee Y. J., Chung S. S., Jung H. S., Park S. G., Park K. S. (2010) Biochem. Biophys. Res. Commun. 397, 735–739 [DOI] [PubMed] [Google Scholar]
- 36. Jiao P., Ma J., Feng B., Zhang H., Alan Diehl J., Eugene Chin Y., Yan W., Xu H. (2011) Obesity 19, 483–491 [DOI] [PubMed] [Google Scholar]
- 37. Okada T., Haze K., Nadanaka S., Yoshida H., Seidah N. G., Hirano Y., Sato R., Negishi M., Mori K. (2003) J. Biol. Chem. 278, 31024–31032 [DOI] [PubMed] [Google Scholar]
- 38. Podrez E. A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., Finton P. J., Shan L., Gugiu B., Fox P. L., Hoff H. F., Salomon R. G., Hazen S. L. (2002) J. Biol. Chem. 277, 38503–38516 [DOI] [PubMed] [Google Scholar]
- 39. Podrez E. A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., Finton P. J., Shan L., Febbraio M., Hajjar D. P., Silverstein R. L., Hoff H. F., Salomon R. G., Hazen S. L. (2002) J. Biol. Chem. 277, 38517–38523 [DOI] [PubMed] [Google Scholar]
- 40. Greenberg M. E., Li X. M., Gugiu B. G., Gu X., Qin J., Salomon R. G., Hazen S. L. (2008) J. Biol. Chem. 283, 2385–2396 [DOI] [PubMed] [Google Scholar]
- 41. Zhang W. H., Liu J., Xu G., Yuan Q., Sayre L. M. (2003) Chem. Res. Toxicol. 16, 512–523 [DOI] [PubMed] [Google Scholar]
- 42. Sayre L. M., Arora P. K., Iyer R. S., Salomon R. G. (1993) Chem. Res. Toxicol. 6, 19–22 [DOI] [PubMed] [Google Scholar]
- 43. Hidalgo F. J., Nogales F., Zamora R. (2008) Food Chem. Toxicol. 46, 43–48 [DOI] [PubMed] [Google Scholar]
- 44. Njoroge F. G., Sayre L. M., Monnier V. M. (1987) Carbohydr. Res. 167, 211–220 [DOI] [PubMed] [Google Scholar]
- 45. Miyazawa T., Nakagawa K., Shimasaki S., Nagai R. (2010) Amino Acids, doi: 10.1007/s00726-010-0772-3 [DOI] [PubMed] [Google Scholar]
- 46. Epand R. F., Mishra V. K., Palgunachari M. N., Anantharamaiah G. M., Epand R. M. (2009) Biochim. Biophys. Acta 1788, 1967–1975 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Razinkov V. I., Melikyan G. B., Epand R. M., Epand R. F., Cohen F. S. (1998) J. Gen. Physiol. 112, 409–422 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Tabas I. (2009) Antioxid. Redox. Signal. 11, 2333–2339 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Sanson M., Augé N., Vindis C., Muller C., Bando Y., Thiers J. C., Marachet M. A., Zarkovic K., Sawa Y., Salvayre R., Nègre-Salvayre A. (2009) Circ. Res. 104, 328–336 [DOI] [PubMed] [Google Scholar]
- 50. Gargalovic P. S., Imura M., Zhang B., Gharavi N. M., Clark M. J., Pagnon J., Yang W. P., He A., Truong A., Patel S., Nelson S. F., Horvath S., Berliner J. A., Kirchgessner T. G., Lusis A. J. (2006) Proc. Natl. Acad. Sci. 103, 12741–12746 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. West J. D., Marnett L. J. (2005) Chem. Res. Toxicol. 18, 1642–1653 [DOI] [PubMed] [Google Scholar]
- 52. Devries-Seimon T., Li Y., Yao P. M., Stone E., Wang Y., Davis R. J., Flavell R., Tabas I. (2005) J. Cell Biol. 171, 61–73 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Karaskov E., Scott C., Zhang L., Teodoro T., Ravazzola M., Volchuk A. (2006) Endocrinology 147, 3398–3407 [DOI] [PubMed] [Google Scholar]